According to market research, the Hypercoagulability Treatment industry is projected to reach a market value of US$ 670 million in 2023 and US$ 1,317.99 million by 2033, exhibiting a CAGR of 7% during the forecast period. Between 2018 and 2022, the market grew at a CAGR of 4%.
For In-depth insights, Download Sample Copy@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16682
The market’s growth can be attributed to an increase in awareness about hypercoagulability and its adverse effects, as well as a rise in the incidence of conditions that increase the risk of hypercoagulability. This, in turn, is driving demand for treatment options, which is likely to fuel the development of new and innovative therapies in the future. Additionally, the market is anticipated to grow due to the increasing prevalence of hypercoagulability and a greater focus on improving treatment outcomes for patients.
As a result of the industry’s positive growth outlook, numerous startups are entering the market, such as Novela Neurotechnology, a US-based startup that has developed an AI-driven platform called Neureka to speed up drug discovery by decoding neurological activity in the brain.
North America is expected to hold a significant share of the market, accounting for approximately 40% of the total market value during the forecast period, primarily due to the region’s high prevalence of hypercoagulability. Additionally, government initiatives and research partnerships are boosting market growth in North America. The Asia Pacific market is also poised for growth, with a focus on point-of-care healthcare and a rise in the number of hospitals in India and China presenting a promising market opportunity globally.
Avail Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-16682
Key Takeaways from the Market Study
- From 2018 to 2022, the Hypercoagulability Treatment market grew at a CAGR of 4%.
- The global Hypercoagulability Treatment market is expected to grow with a 7% CAGR during 2023 to 2033.
- As of 2033, the Hypercoagulability Treatment Market is expected to reach US$ 1317.99 Million
- According to the FMI analysis, hospitals account for the largest market share.
- North America is expected to possess 40% market share for the Hypercoagulability Treatment market.
- The Asia Pacific market is predicted to increase significantly throughout the forecast period, with a share of 20% during the forecast period.
“A series of international level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering Hypercoagulability Treatment.” says an FMI analyst
Market Competition
Key players in the market include pharmaceutical companies such as Bristol-Myers Squibb, Pfizer, Sanofi, Johnson & Johnson and Roche along with the healthcare providers and technology companies among other global players.
- In May 2020, the US Food and Drug Administration (FDA) approved Qinlock (ripretinib) tablets as a fourth-line treatment option for advanced gastrointestinal stromal tumors (GIST). Qinlock is a kinase inhibitor and is indicated for patients who have received three or more prior kinase inhibitor treatments, including imatinib. The approval was based on results of a randomized, double-blind, placebo-controlled clinical trial that enrolled 129 patients with advanced GIST. The trial showed that progression-free survival (PFS) was longer in the group receiving Qinlock compared to the placebo group. Qinlock was administered once a day in 28-day cycles until disease progression or intolerable side effects. After disease progression, patients in the placebo group had the option to switch to Qinlock.
More Insights Available
North America dominates the hypercoagulability market due to the high prevalence of thrombophilia in the region, favorable reimbursement policies, and the presence of major market players. Europe is also a significant market for hypercoagulability, driven by the increasing awareness about the condition and the growing adoption of advanced diagnostic tests and personalized treatments.
Customization Available@ https://www.futuremarketinsights.com/customization-available/rep-gb-16682
Key Segments Profiled in the Hypercoagulability Treatment Industry Survey
Drugs:
- Heparin
- Warfarin
- Direct Thrombin Inhibitor
Route of Administration:
- Oral
- Injectable
End Users:
- Hospitals
- Speciality Centers
About Future Market Insights, Inc.
Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs
